Pages

Showing posts with label ponv. Show all posts
Showing posts with label ponv. Show all posts

Friday, January 22, 2016

ROLAPITANT



🔹Its a Neurokinin-1 receptor antagonist . NK-1 receptors are highly concentrated in the vomiting center of the brain and bind a neurokinin termed substance P; activation of NK-1 receptors by substance P plays a central role in eliciting chemotherapy-induced nausea and vomiting

Blocking the interaction of substance P at the NK-1 receptor, NK-1 receptor antagonists improve the management of nausea and vomiting

🔹Comes in Tablet form (90 mg)

🔹Indication: In combination with other antiemetic agents, to prevent nausea and vomiting associated with emetogenic cancer chemotherapy 

🔹Especially useful in preventing delayed phase chemotherapy induced nausea and vomiting

🔹Highly emetogenic chemotherapy

Day 1: Rolapitant 180 mg PO 1-2 hr before chemotherapy PLUS dexamethasone 20 mg PO 30 minutes before chemotherapy PLUS 5HT-3 antagonist
 
Days 2-4: Dexamethasone 8 mg PO BID

🔹Moderately emetogenic chemotherapy

Day 1: Rolapitant 180 mg PO 1-2 hr before chemotherapy PLUS dexamethasone 20 mg PO 30 minutes before chemotherapy PLUS 5HT-3 antagonist 

Days 2-4: 5HT-3 antagonist 

🔹Contraindicated with the use of thioridazine ( risk of arrhythmias due to increased thioridazine levels)

Safety not established for pediatric use and in pregnancy 

🔹SIDE EFFECTS 

Decreased appetite (9%), Neutropenia (7-9%)
Dizziness (6%)

🔹Rolapitant vs Aprepitant 

Rolapitant has been studied as a one-time dose on day 1 of chemotherapy, while aprepitant is recommended to be given on days 1 through 3. Rolapitant does not inhibit CYP 2C9 or 3A4 enzymes, whereas aprepitant induces CYP 2C9 and 3A4 and moderately inhibits 3A4.3,4 As a result, aprepitant can interfere with warfarin, hormonal contraceptives, and certain chemotherapy, among other drugs.



Ref: WHO DRUG INFORMATION, VOL 29, number 3, 2015

Medscape Reference , http://reference.medscape.com/drug/varubi-rolapitant


Monday, December 28, 2015

TRAMADOL AND ONDANSETRON: THEY ARE NOT A GOOD PAIR ! ; WHY FORCING THEM TO LIVE TOGETHER ?



Tramadol- highlights 
➖➖➖➖➖➖➖➖

✔️both opioid and non-opioid modes of action. . 
(1) inhibition of noradrenaline re-uptake 
(2)increased release and decreased re-uptake of serotonin in the spinal cord, and 
(3)a weak effect on mu opioid receptors

✔️The weak, opioid effect is mediated by an active metabolite, (+)-M1 (O-desmethyltramadol), formed via the genetically polymorphic P450 CYP2D6 iso-enzyme system. The biological activity of this system is variable, and individuals may be classified as extensive or poor metabolisers of tramadol. 

✔️Tramadol’s affinity for opioid receptors is about 6000 times weaker than morphine, but the (+)-M1 metabolite has an affinity about 200 times greater than tramadol. Poulsen et al. report much higher concentrations of the (+)-M1 metabolite and greater analgesic efficacy of tramadol in extensive metabolisers compared to poor metabolisers. Also noted was a reduction of nausea, vomiting and tiredness amongst poor metabolisers

Ondansetron-highlights
➖➖➖➖➖➖➖➖➖

✔️Ondansetron competitively antagonises serotonin, subtype 3 (5-HT3) receptors in the CTZ and enteric neurones. 

✔️ Peripheral 5-HT3 receptors are also involved in nociceptive pathways and ondansetron may alter 5-HT3 nociceptive responses at the level of dorsal horn neurones

✔️ Ondansetron can block sodium channels in a similar fashion to local anaesthetic agents, and exhibit agonist activity at mu opioid receptors, thus resulting in a peripheral anti-nociceptive effect.

Tramadol + Ondansetron 
➖➖➖➖➖➖➖➖➖

✔️PONV due to Tramadol is often managed with a competitive serotonin antagonist, ondansetron

✔️ There is evidence that the concurrent use of these two drugs results in a mutual reduction of effect—tramadol is a less potent analgesic and ondansetron is a less effective as an antiemetic. 

✔️ But the effect of ondansetron on tramadol consumption diminished with time. 

✔️ De Witte et al. found a significant (50%) increase in cumulative tramadol consumption during the first post-operative hour when patients were given ondansetron along with Tramadol.

✔️ Ondansetron is, in part, metabolised by the CYP2D6 iso-enzyme system—an iso-enzyme system responsible for formation of an active tramadol metabolite that has analgesic effect . Competition for this metabolic pathway may result in a reduction in formation of the (+)-M1 metabolite of tramadol and a consequent reduction in analgesic efficacy.

DO YOU KNOW❓😳 additional points➕

✔️ There is animal and human evidence that both tramadol and ondansetron have local anaesthetic type properties.

✔️ Ondansetron was approximately fifteen times more potent than lignocaine and may well be a prototype molecule for the development of a new group of local anaesthetic agents. 

✔️ These findings are further supported in a human clinical study by Memis et al.which showed that tramadol and ondansetron both significantly reduced the pain associated with the injection of the neuromuscular blocking drug, rocuronium.
(Ref: J.H. Ye, W.C. Mui, J. Ren, T.E. Hunt, W.H. Wu, V.K. Zbuzek Ondansetron exhibits the properties of a local anesthetic. Anesth. Analg., 85 (1997), pp. 1116–1121)

✔️Tropisetron and granisetron are able to reverse an acetaminophen-mediated analgesia completely.
 



〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰

References:

Anaesthesia. 2015 Feb;70(2):209-18. doi: 10.1111/anae.12948. Epub 2014 Dec 10.
The effect of ondansetron on the efficacy of postoperative tramadol: a systematic review and meta-analysis of a drug interaction.
Stevens AJ1, Woodman RJ, Owen H.

Ondansetron Inhibits the Analgesic Effects of Tramadol: A Possible 5-HT3 Spinal Receptor Involvement in Acute Pain in Humans
Arcioni, Roberto MD*,; della Rocca, Marco MD*,; Romanò, Sarah MD*,; Romano, Rocco MD†,; Pietropaoli, Paolo MD*, and; Gasparetto, Alessandro MD*

ScienceDirect Review
Aspects of tramadol and ondansetron interactions Bruce Hammonds, David A. Sidebotham, Brian J. Anderson,